OBJECTIVE: Resolvin D1 (RvD1) limits neutrophil recruitment during acute inflammation and is derived from omega-3 docosahexaenoic acid to promote catabasis. The contribution of its specific receptors, the lipoxin A(4)/Annexin-A1 receptor formyl-peptide receptor 2 (FPR2/ALX) and the orphan receptor G-protein-coupled receptor 32 (GPR32) are of considerable interest. METHODS AND RESULTS: RvD1 reduced human polymorphonuclear leukocytes recruitment to endothelial cells under shear conditions as quantified using a flow chamber system. Receptor-specific antibodies blocked these anti-inflammatory actions of RvD1, with low (1 nmol/L) concentrations sensitive to GPR32 blockade, while the higher (10 nmol/L) concentration appeared FPR2/ALX-specific. Interestingly, polymorphonuclear leukocytes surface expression of FPR2/ALX but not GPR32 increased following activation with pro-inflammatory stimuli, corresponding with secretory vesicle mobilization. Lipid mediator metabololipidomics carried out with 24-hour exudates revealed that RvD1 in vivo gave a significant reduction in the levels of a number of pro-inflammatory mediators including prostaglandins and leukotriene B(4). These actions of RvD1 were abolished in fpr2 null mice. CONCLUSIONS: Pro-resolving lipid mediators and their receptors, such as RvD1 and the 2 G-protein-coupled receptors, studied here regulate resolution and may provide new therapeutic strategies for diseases with a vascular inflammatory component.
OBJECTIVE: Resolvin D1 (RvD1) limits neutrophil recruitment during acute inflammation and is derived from omega-3 docosahexaenoic acid to promote catabasis. The contribution of its specific receptors, the lipoxin A(4)/Annexin-A1 receptor formyl-peptide receptor 2 (FPR2/ALX) and the orphan receptor G-protein-coupled receptor 32 (GPR32) are of considerable interest. METHODS AND RESULTS: RvD1 reduced human polymorphonuclear leukocytes recruitment to endothelial cells under shear conditions as quantified using a flow chamber system. Receptor-specific antibodies blocked these anti-inflammatory actions of RvD1, with low (1 nmol/L) concentrations sensitive to GPR32 blockade, while the higher (10 nmol/L) concentration appeared FPR2/ALX-specific. Interestingly, polymorphonuclear leukocytes surface expression of FPR2/ALX but not GPR32 increased following activation with pro-inflammatory stimuli, corresponding with secretory vesicle mobilization. Lipid mediator metabololipidomics carried out with 24-hour exudates revealed that RvD1 in vivo gave a significant reduction in the levels of a number of pro-inflammatory mediators including prostaglandins and leukotriene B(4). These actions of RvD1 were abolished in fpr2 null mice. CONCLUSIONS: Pro-resolving lipid mediators and their receptors, such as RvD1 and the 2 G-protein-coupled receptors, studied here regulate resolution and may provide new therapeutic strategies for diseases with a vascular inflammatory component.
Authors: Yee-Ping Sun; Sungwhan F Oh; Jasim Uddin; Rong Yang; Katherine Gotlinger; Eric Campbell; Sean P Colgan; Nicos A Petasis; Charles N Serhan Journal: J Biol Chem Date: 2007-01-23 Impact factor: 5.157
Authors: Antonio Recchiuti; Sriram Krishnamoorthy; Gabrielle Fredman; Nan Chiang; Charles N Serhan Journal: FASEB J Date: 2010-10-18 Impact factor: 5.191
Authors: Thea Morris; Melanie Stables; Paul Colville-Nash; Justine Newson; Geoffrey Bellingan; Patricia M de Souza; Derek W Gilroy Journal: Proc Natl Acad Sci U S A Date: 2010-04-26 Impact factor: 11.205
Authors: Matthew Spite; Lucy V Norling; Lisa Summers; Rong Yang; Dianne Cooper; Nicos A Petasis; Roderick J Flower; Mauro Perretti; Charles N Serhan Journal: Nature Date: 2009-10-29 Impact factor: 49.962
Authors: Vasundhara Kain; Kevin A Ingle; Romain A Colas; Jesmond Dalli; Sumanth D Prabhu; Charles N Serhan; Medha Joshi; Ganesh V Halade Journal: J Mol Cell Cardiol Date: 2015-04-11 Impact factor: 5.000
Authors: Alessandro Matte; Antonio Recchiuti; Enrica Federti; Bérengère Koehl; Thomas Mintz; Wassim El Nemer; Pierre-Louis Tharaux; Valentine Brousse; Immacolata Andolfo; Alessia Lamolinara; Olga Weinberg; Angela Siciliano; Paul C Norris; Ian R Riley; Achille Iolascon; Charles N Serhan; Carlo Brugnara; Lucia De Franceschi Journal: Blood Date: 2018-11-07 Impact factor: 22.113
Authors: Tomohiro Kurihara; Caroline N Jones; Yong-Ming Yu; Alan J Fischman; Susumu Watada; Ronald G Tompkins; Shawn P Fagan; Daniel Irimia Journal: FASEB J Date: 2013-02-21 Impact factor: 5.191
Authors: Magnus Bäck; William S Powell; Sven-Erik Dahlén; Jeffrey M Drazen; Jilly F Evans; Charles N Serhan; Takao Shimizu; Takehiko Yokomizo; G Enrico Rovati Journal: Br J Pharmacol Date: 2014-07-12 Impact factor: 8.739
Authors: Bishuang Cai; Edward B Thorp; Amanda C Doran; Manikandan Subramanian; Brian E Sansbury; Chyuan-Sheng Lin; Matthew Spite; Gabrielle Fredman; Ira Tabas Journal: Proc Natl Acad Sci U S A Date: 2016-05-19 Impact factor: 11.205